A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Paliperidone (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 25 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 01 Mar 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.